Application No. 10/500,284 Amendment dated December 3, 2007

After Final Office Action of July 2, 2007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the

Docket No.: 1291-0215PUS1

application.

Listing of Claims:

1. (Currently Amended) A method for treating protracted establishing effective term

labor in women, comprising the step of:

administering to a pregnant woman an effective amount of at least one sulfated

glycosaminoglycan selected from the group consisting of heparan sulfate, depolymerised

heparan sulfate, dermatan sulfate, depolymerised dermatan sulfate, low molecular weight

heparan heparin and depolymerised heparan heparin, said sulfated glycosaminoglycan having an

anticoagulant activity of 100 BP units/mg or less to prophylactically prime or curatively treat the

cervix and myometrium and for the prevention or treatment of slow progress of term labor.

2. (Previously Presented) The method according to claim 1, wherein the at least one

glycosaminoglycan comprises at least one glycosaminoglycan selected from the group

consisting of heparan sulfate and depolymerised heparan sulfate.

(Cancelled).

Amendment dated December 3, 2007 After Final Office Action of July 2, 2007

4. (Previously Presented) The method according to claim 1, wherein the at least one

glycosainoglycan comprises at least one glycosaminoglycan selected from the group consisting

of dermatan sulfate and depolymerised dermatan sulfate.

5. (Currently Amended) The method according to claim 1, wherein the at least one

glycosaminoglycan comprises depolymerised heparan heparin having an average molecular

weight below 10 000 Da.

6. (Previously Presented) The method according to any one claims 1, 2, 4 or 5, wherein

the at least one glycosaminoglycan has an anticoagulant activity of 30 BP units/mg or less.

7. (Cancelled).

8. (Previously Presented) The method according to claim 1, wherein the at least one

glycosaminoglycan is administered in combination with oxytocin.

9. (Previously Presented) The method according to claim 1, wherein the at least one

glycosaminoglycan is administered topically in a topical pharmaceutical preparation.

Application No. 10/500,284 Docket No.: 1291-0215PUS1

Amendment dated December 3, 2007 After Final Office Action of July 2, 2007

10. (Previously Presented) The method according to claim 1, wherein the at least one

glycosaminoglycan is administered in a parenteral pharmaceutical preparation.

11. (Currently Amended) The method according to claim 5, wherein the at least one

glycosaminoglycan comprises depolymerised heparan heparin having a molecular weight not

higher than 6,000 Da.

12. (New) A method according to claim 1, wherein the step of administering to a

pregnant woman occurs only during term labor.

13. (New) A method according to claim 1, wherein the step of administering is to a

pregnant woman not eligible for an antithrombotic therapy.

14. (New) A method according to claim 1, wherein the least one sulfated

glycosaminoglycans is administered for a period of 1-30 days starting during the period wherein

labor is defined as term labor.

Application No. 10/500,284 Amendment dated December 3, 2007

After Final Office Action of July 2, 2007

15. (New) A method according to claim 1, wherein the step of administering is to a

Docket No.: 1291-0215PUS1

pregnant woman not eligible for an antithrombotic therapy and the least one sulfated

glycosaminoglycans is administered for a period of 1-30 days starting during the period wherein

labor is defined as term labor.